15038 studies
Obesity, hypertension, and chronic kidney disease (CKD) constitute the deadly trinity of modern threats for populations of both developed and developing countries. These diseases (together with type 2 diabetes) are closely linked in their pathophysio…
Semaglutide is a glucagon-like peptide-1 receptor agonist used in the treatment of type 2 diabetes mellitus and management of obesity. Associations of glucagon-like peptide-1 receptor agonist use with psychiatric adverse events and suicidal behavior…
This study aimed to identify the prevalence of prescription weight loss medication use among boys and men, describe the sociodemographic differences between those who did and did not report use, and explore differences in eating disorder attitudes an…
Obesity is associated with several comorbidities including Heart Failure with preserved Ejection Fraction (HFpEF), Metabolic dysfunction-Associated SteatoHepatitis (MASH), also termed MetALD when MASH patients have increased alcohol intake. The world…
Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used as anti-obesity agents, there are individual differences between these agents, thus making it difficult to achieve optimal treatment efficacy. This study aimed to determine…
Introduction Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are used in the treatment of type 2 diabetes mellitus and obesity. A side effect of GLP1-RAs is delayed gastric emptying, which could increase the risk of pulmonary aspiration. This ex…
Incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are produced in the gut and play critical roles linking the processes of eating and digestion with the release of insulin from the pancreas and…
Obesity remains a critical global health issue with profound medical and economic implications. While injectable medications such as semaglutide (Wegovy®) and tirzepatide (Zepbound®) have demonstrated significant efficacy, the development of novel or…
IMPORTANCE: Glucagon-like peptide 1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, provide cardiometabolic benefits to patients with type 2 diabetes and obesity, but their potential benefits in mitigating neurodegenerative and cer…
INTRODUCTION: Although the onset and progression of diabetic microvascular complications are linked to glycemic control, various antihyperglycemic drugs with distinct treatment targets may positively impact microvascular lesions beyond their glucose-…
INTRODUCTION: According to the Obesity Medicine Association, obesity is a chronic, progressive, relapsing, multifactorial and treatable neurobehavioral disease. A small number of drugs have been approved by the Food & Drug Administration (FDA) for we…
This systematic review and meta-analysis compared the weight loss efficacy of tirzepatide versus semaglutide in overweight and obese adults through direct comparative studies. We systematically searched PubMed, Excerpta Medica database (EMBASE), Web…
Obesity is a chronic disease with multiple causes and serious complications. Treatments include lifestyle modifications and, for severe cases, medication. Today, molecules such as liraglutide and semaglutide are showing promising results in terms of…
OBJECTIVE: To determine whether a slower, flexible titration regimen of semaglutide would improve adherence and reduce gastrointestinal adverse events (GI-AEs) compared with the label-recommended regimen in patients with type 2 diabetes (T2D). RESEAR…
Semaglutide, a glucagon-like peptide-1 receptor agonist, is known for weight reduction and glycemic control and is approved to lower major cardiovascular event risk in adults with overweight or obesity. While individual trials have explored its effec…
BACKGROUND: Adipose tissue secretome plays a crucial role in the mechanisms of metabolic diseases. Weight loss has a favourable effect on the adipose tissue secretome and prevents the development of type 2 diabetes mellitus (T2DM) and its complicatio…
AIMS: The effects of semaglutide on non-overweight patients with type 2 diabetes (T2D) remain unclear. We retrospectively compared all-cause mortality, cardiovascular outcomes, and adverse events in patients with T2D with a body mass index (BMI) < 25…